Hormone Replacement Therapy and Stroke: The Current State of Knowledge and Directions for Future Research

ABSTRACT

The Women’s Health Initiative, which reported an increased risk of stroke with hormone therapy (HT), has had a major impact on the use of these drugs. The increased risk was unexpected because experimental animal studies showed estrogen reduced stroke volume and estrogen improves endothelial-dependent blood flow and improves lipid profiles in humans. The mechanisms of risk are uncertain because of the complexity of actions of estrogen in different doses, with or without progesterone, and the presence or absence of atherosclerotic risk factors. Therefore, future research should focus on identifying the mechanism(s) of risk, determining the differential impact of estrogen on stroke compared with heart disease, and identifying women with vasomotor symptoms who may be at risk of stroke with short-term HT use.

Hormone replacement therapy - ischemic stroke - risk factors

REFERENCES

• 1 Heart disease and stroke statistics .American Heart Association Heart and Stroke Statistics: 2003 Update. 
• 2 Chan W S, Ray J, Wai E K et al.. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence.  Arch Intern Med. 2004;  164 741-747
• 3 Kemmeren J M, Tanis B C, van den Bosch M A et al.. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke.  Stroke. 2002;  33 1202-1208
• 4 Siritho S, Thrift A G, McNeil J J et al.. Risk of ischemic stroke among users of the oral contraceptive pill. The Melbourne Risk Factor Study (MERFS) Group.  Stroke. 2003;  34 1575-1580
• 5 Gillum L A, Mamidipudi S K, Johnston S C. Ischemic stroke risk with oral contraceptives: a meta-analysis.  JAMA. 2000;  284 72-78
• 6 Rosenberg S H, Fausone V, Clark R. The role of estrogens as a risk factor for stroke in postmenopausal women.  West J Med. 1980;  133 292-296
• 7 Falkeborn M, Persson I, Terent A et al.. Hormone replacement therapy and the risk of stroke.  Arch Intern Med. 1993;  153 1201-1209
• 8 Grodstein F, Stampfer M J, Manson J E et al.. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.  N Engl J Med. 1996;  335 453-461
• 9 Petitti D B, Sidney S, Quesenberry Jr C P, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy.  Stroke. 1998;  29 23-28
• 10 Fung M M, Barrett-Connor E, Bettencourt R R. Hormone replacement therapy and stroke risk in older women.  J Womens Health. 1999;  8 359-364
• 11 Pedersen A T, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke.  Lancet. 1997;  350 1277-1283
• 12 Grodstein F, Manson J E, Colditz G A et al.. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.  Ann Intern Med. 2000;  133 933-941
• 13 Lemaitre R N, Heckbert S R, Psaty B M et al.. Hormone replacement therapy and associated risk of stroke in postmenopausal women.  Arch Intern Med. 2002;  162 1954-1960
• 14 Sourander L, Rajala T, Raiha I et al.. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT).  Lancet. 1998;  352 1965-1969
• 15 Pfeffer R, Van Den Noort S. Estrogen use and stroke risk in postmenopausal women.  Am J Epidemiol. 1976;  103 445-456
• 16 Wilson P W, Garrison R J, Castelli W P. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50.  N Engl J Med. 1985;  313 1038-1043
• 17 Finucane F, Madans J H, Bush T L, Wolf P H, Kleinman J C. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort.  Arch Intern Med. 1993;  153 73-79
• 18 Lindenstrom E, Boysen G, Nyboe J. Lifestyle factors and risk of cerebrovascular disease in women: the Copenhagen City Heart Study.  Stroke. 1993;  24 1468-1472
• 19 Lokkegaard E, Jovanovic Z, Heitmann B L et al.. Increased risk of stroke in hypertensive women using hormone therapy.  Arch Neurol. 2003;  60 1379-1384
• 20 Hulley S, Grady D, Bush T et al.. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.  JAMA. 1998;  280 605-613
• 21 Simon J A, Hsia J, Cauley J A et al.. Postmenopausal hormone therapy and risk of stroke: the heart and estrogen-progestin replacement study (HERS).  Circulation. 2001;  103 638-642
• 22 Viscoli C M, Brass L M, Kernan W N et al.. A clinical trial of estrogen-replacement therapy after ischemic stroke.  N Engl J Med. 2001;  345 1243-1249
• 23 Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
• 24 The Women's Health Initiative Steering Committee . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy.  JAMA. 2004;  291 1701-1712
• 25 Wassertheil-Smoller S, Hendrix S L, Limacher M et al.. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial.  JAMA. 2003;  289 2673-2684
• 26 Grodstein F, Clarkson T B, Manson J E. Understanding the divergent data on postmenopausal hormone therapy.  N Engl J Med. 2003;  348 645-650
• 27 Matthews K A, Kuller L H, Wing R R, Meilahn E N, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers?.  Am J Epidemiol. 1996;  143 971-978
• 28 Alkayed N, Murphy S, Traystman R, Hurn P, Miller V. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats.  Stroke. 2000;  31 161-168
• 29 Yang S H, Shi J, Day A L, Simpkins J W. Estradiol exerts neuroprotective effects when administered after ischemic insult.  Stroke. 2000;  31 745-749 , discussion 749-750
• 30 McCullough L D, Alkayed N J, Traystman R J, Williams M J, Hurn P D. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke.  Stroke. 2001;  32 796-802
• 31 Hurn P D, Brass L M. Estrogen and stroke: a balanced analysis.  Stroke. 2003;  34 338-341
• 32 Vegeto E, Bonincontro C, Pollio G et al.. Estrogen prevents the LPS-induced inflammatory response in microglia.  J Neurosci. 2001;  21 1809-1818
• 33 Zhang L, Nair A, Krady K et al.. Estrogen stimulated microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice.  J Clin Invest. 2004;  113 85-95
• 34 Marriott L, Hauss-Wegrzyniak B, Benton R, Vraniak P, Wenk G. Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation.  Behav Neurosci. 2002;  116 902-911
• 35 Lim S C, Caballero E, Arora S et al.. The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes.  J Clin Endocrinol Metab. 1999;  84 4159-4164
• 36 Hashimoto M, Akishita M, Eto M et al.. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle.  Circulation. 1995;  92 3431-3435
• 37 Lieberman E H, Gerhard M D, Uehata A et al.. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women.  Ann Intern Med. 1994;  121 936-941
• 38 Gerhard M, Walsh B W, Tawakol A et al.. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women.  Circulation. 1998;  98 1158-1163
• 39 Majmudar N G, Robson S C, Ford G A. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity.  J Clin Endocrinol Metab. 2000;  85 1577-1583
• 40 Gilligan D M, Badar D M, Panza J A, Quyyumi A A, Cannon ROI. Coronary heart disease/myocardial infarction/peripheral vascular disease: acute vascular effects of estrogen in postmenopausal women.  Circulation. 1994;  90 786-791
• 41 Guetta V, Quyyumi A A, Prasad A et al.. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women.  Circulation. 1997;  96 2795-2801
• 42 Best PJM, Berger P B, Miller V M, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women.  Ann Intern Med. 1998;  128 285-288
• 43 Koh K K, Kang M H, Jin D K et al.. Vascular effects of estrogen in type II diabetic postmenopausal women.  J Am Coll Cardiol. 2001;  38 1409-1415
• 44 Honisett S Y, Stojanovska L, Sudhir K et al.. Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone.  J Clin Endocrinol Metab. 2004;  89 4615-4619
• 45 Gangar K F, Vyas S, Whitehead M et al.. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause.  Lancet. 1991;  338 839-842
• 46 Bui M N, Arai A E, Hathaway L et al.. Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women.  Am J Cardiol. 2002;  90 82-85
• 47 Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial.  J Am Coll Cardiol. 2000;  36 1789-1796
• 48 Nabulsi A A, Folsom A R, Szklo M et al.. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness.  Circulation. 1996;  94 1857-1863
• 49 Espeland M A, Applegate W, Furberg C et al.. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women.  Am J Epidemiol. 1995;  142 1011-1019
• 50 Hodis H N, Mack W J, Lobo R A et al.. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 2001;  135 939-953
• 51 Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial.  Arterioscler Thromb Vasc Biol. 2001;  21 262-268
• 52 Ohkura T, Teshima Y, Isse K et al.. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women.  Menopause: Journal of the North American Menopause Society. 1995;  2 13-18
• 53 Penotti M, Sironi L, Castiglioni E et al.. Blood flow in the internal carotid and middle cerebral arteries: effects of continuous oral conjugated equine estrogens administration with monthly progestogen supplementation on postmenopausal women.  Menopause. 1999;  6 225-229
• 54 Penotti M, Farina M, Castiglioni E et al.. Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: a randomized crossover study.  Am J Obstet Gynecol. 1996;  175 606-611
• 55 Grady D, Wenger N K, Herrington D M et al.. Postmenopausal hormone therapy increases risk for venous thromboembolic disease.  Ann Intern Med. 2000;  132 689-696
• 56 Cushman M, Meilahn E N, Psaty B M et al.. Hormone replacement therapy, inflammation, and hemostasis in elderly women.  Arterioscler Thromb Vasc Biol. 1999;  19 893-899
• 57 McKenzie J, Jaap A J, Gallacher S et al.. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safe with respect to vascular risk?.  Clin Endocrinol (Oxf). 2003;  59 682-689
• 58 Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G et al.. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial.  Arterioscler Thromb Vasc Biol. 1997;  17 3071-3078
• 59 Teede H J, McGrath B P, Smolich J J et al.. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.  Arterioscler Thromb Vasc Biol. 2000;  20 1404-1409
• 60 Glueck C J, Wang P, Fontaine R N, Sieve-Smith L, Lang J E. Estrogen replacement therapy, thrombophilia, and atherothrombosis.  Metabolism. 2002;  51 724-732
• 61 Shattil S, Hoxie J, Cunningham M, Brass L. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation.  J Biol Chem. 1985;  260 11107-11114
• 62 Kurrelmeyer K, Becker L, Becker D et al.. Platelet hyperreactivity in women from families with premature atherosclerosis.  J Am Med Womens Assoc. 2003;  58 272-277
• 63 Weiss E J, Bray P F, Tayback M et al.. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.  N Engl J Med. 1996;  334 1090-1094
• 64 Boudoulas K D, Cooke G E, Roos C M, Bray P F, Goldschmidt-Clermont P. The PI^A polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation.  Arch Pathol Lab Med. 2001;  125 112-115
• 65 Reiner A P, Kumar P N, Schwartz S M et al.. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women.  Stroke. 2000;  31 1628-1633
• 66 Brass L. Hormones and cardiovascular disease: what a difference a decade makes. Presented at International Stroke Meeting San Diego, CA; February 2004
• 67 Herrington D, Vittinghoff E, Lin F et al.. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).  Circulation. 2002;  105 2962-2967
• 68 Bushnell C D, Newby L K, Goldstein L B et al.. Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS).  Neurology. 2004;  62 968-970
• 69 PROGRESS Collaborative Group . Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.  Lancet. 2001;  358 1033-1041
• 70 Kjeldsen S E, Dahlof B, Devereux R B et al.. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) Substudy.  JAMA. 2002;  288 1491-1498
• 71 Report of the NINDS Stroke Progress Review Group .2002: 1-116
• 72 Anjega B G, Shlipak M G, Go A S et al.. Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women.  J Am Coll Cardiol. 2001;  38 1297-1301
• 73 Paganini-Hill A, Ross R K, Henderson B E. Postmenopausal oestrogen treatment and stroke: a prospective study.  BMJ. 1988;  297 519-522
• 74 Schairer C, Adami H-O, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy.  Epidemiology. 1997;  8 59-65
• 75 Thompson S G, Meade T W, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women.  J Epidemiol Community Health. 1989;  43 173-178
• 76 Grady D, Herrington D, Bittner V et al.. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II).  JAMA. 2002;  288 49-57